Rifampin-moxifloxacin-metronidazole combination therapy for severe Hurley Stage 1 Hidradenitis Suppurativa: prospective short-term trial and one-year follow-up in 28 consecutive patients - Institut Pasteur Access content directly
Journal Articles Journal of The American Academy of Dermatology Year : 2020

Rifampin-moxifloxacin-metronidazole combination therapy for severe Hurley Stage 1 Hidradenitis Suppurativa: prospective short-term trial and one-year follow-up in 28 consecutive patients

Fichier principal
Vignette du fichier
1-s2.0-S0190962220300499-main.pdf (426.57 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

pasteur-02547275 , version 1 (19-04-2020)

Licence

Attribution - NonCommercial

Identifiers

Cite

Maïa Delage, J.-P. Jais, T. Lam, H. Guet-Revillet, Marie-Noëlle Ungeheuer, et al.. Rifampin-moxifloxacin-metronidazole combination therapy for severe Hurley Stage 1 Hidradenitis Suppurativa: prospective short-term trial and one-year follow-up in 28 consecutive patients. Journal of The American Academy of Dermatology, 2020, ⟨10.1016/j.jaad.2020.01.007⟩. ⟨pasteur-02547275⟩
349 View
525 Download

Altmetric

Share

Gmail Facebook X LinkedIn More